



Biotech Daily

Thursday March 12, 2020

Daily news on ASX-listed biotechnology companies

Biotech Daily Editorial: Covid-19 Coronavirus Claims

A number of companies have made announcements, primarily to calm investors, saying they are not affected by the Covid-19 coronavirus.

Others have said that they have tests, diagnostics and drugs in development or able to be used in managing patients.

Last week, Dr Boreham's Crucible covered the potential risks and benefits to the biotechnology sector and not much has changed since then.

Earlier this week, Polynovo said that it was unaffected by the pandemic and we decided that was not sufficient to be reported.

Mesoblast and Cynata have discussed the potential of stem cells for treating issues following infection from Covid-19, applicable to any cold or influenza infection, as would be the case with the Respiro claim that it "agreed to a request" to supply its Wheezo to three hospitals in China.

Given that Painchek primarily services residential aged care facilities, we believe this announcement (below) is relevant.

We shall not publish 130 companies saying that the Covid-19 does not affect them. Where companies claim they will benefit from the pandemic we shall report that and leave readers to make up their own minds on whether the claims are valid.

David Langsam
Editor

[PAINCHEK](#)

Painchek says “at this stage” the Covid-19 coronavirus is not having an adverse impact on sales and implementation of its pain test for residential aged care customers.

Painchek said the test was “a software as a service technology that is deployed in the [internet] cloud and is not subject to territories or borders that can impact on supply to clients around the globe”, with a minimized need for sales and marketing personnel to have direct access to client premises.

The company said it expected that the need for its pain assessment in residential aged care facilities would continue in a virus challenged world, as regular and reliable pain assessment remains a key duty of care facility operators.

Painchek chief executive officer Philip Daffas said the company was “taking a rational and considered approach to the coronavirus risk factor in our outlook”.

Painchek fell 0.2 cents or 2.2 percent to 8.8 cents with 6.8 million shares traded.